Recombinant Human Mesothelin Protein

<strong>Recombinant Human Mesothelin Protein</strong>_x000D_ <strong>Catalog number:</strong> B2012900_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 32.4 kDa_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Mesothelin Protein, Human; MPF Protein, Human; SMRP Protein, Human_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Morello A, Sadelain M, Adusumilli PS. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors Cancer Discov. 2016 Feb;6(2):133-46._x000D_ 2: Hagerty BL, Pegna GJ, Xu J, Tai CH, Alewine C. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors Biomolecules. 2020 Jun 28;10(7):973._x000D_ 3: Cerise A, Bera TK, Liu X, Wei J, Pastan I. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer Clin Colorectal Cancer. 2019 Sep;18(3):192-199.e1._x000D_ 4: Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity Sci Transl Med. 2014 Nov 5;6(261):261ra151._x000D_ 5: Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ Jr. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor Mol Ther. 2012 Mar;20(3):633-43._x000D_ 6: Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high-affinity human monoclonal antibody to mesothelin Int J Cancer. 2011 May 1;128(9):2020-30._x000D_ 7: Hassan R, Ho M. Mesothelin targeted cancer immunotherapy Eur J Cancer. 2008 Jan;44(1):46-53._x000D_ 8: Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42._x000D_ 9: Dangaj D, Abbott KL, Mookerjee A, Zhao A, Kirby PS, Sandaltzopoulos R, Powell DJ Jr, Lamazière A, Siegel DL, Wolf C, Scholler N. Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody PLoS One. 2011;6(12):e28386._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/30777106">10: Lv J, Zhao R, Wu D, Zheng D, Wu Z, Shi J, Wei X, Wu Q, Long Y, Lin S, Wang S, Wang Z, Li Y, Chen Y, He Q, Chen S, Yao H, Liu Z, Tang Z, Yao Y, Pei D, Liu P, Zhang X, Zhang Z, Cui S, Chen R, Li P. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer J Hematol Oncol. 2019 Feb 18;12(1):18. </a>_x000D_ _x000D_ <strong>Products Related to Recombinant Human Mesothelin Protein can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>